About Goldline Pharmaceutical Limited
Data last updated: 07 January 2026
Goldline Pharmaceutical Limited is a public limited company based in Nagpur, Maharashtra, India. It specialises in pharmaceutical retail and distribution, a part of the broader pharmaceuticals sector. Incorporated on 02 August 2004, the company has been in operation for over 22 years.
Registered with ROC Mumbai under CIN U51397MH2004PLC147806.
Capital: an authorised share capital of ₹13.5 Cr and a paid-up capital of ₹8.71 Cr. Formerly known as Goldline Pharmaceutical Private Limited. It is led by directors including Swapan Khandelwal and Amol Laxmikant Mujumdar.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Nagpur, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹28.06 Cr, a growth of 19% compared to the previous year.
The company has a workforce of approximately 85 employees as per the latest available data.
As per MCA filings, the company has open charges of ₹8.54 Cr and satisfied charges of ₹3.53 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website goldlinepharma.in.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered Address103 F – 1Leelaapartmentshilpahsgsociety Nearsaptagirinagar Shanidham Narend, Ra Nagar, Nagpur, Maharashtra, India – 440015
-
IndustryPharma, Pharmaceutical Retailers & Distributors
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Goldline Pharmaceutical Limited
Goldline Pharmaceutical Limited has one previous CIN (Corporate Identification Number): U51397MH2004PTC147806. The current CIN is U51397MH2004PLC147806, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U51397MH2004PLC147806 | Current |
| U51397MH2004PTC147806 | Previous |
Business Activity of Goldline Pharmaceutical Limited
Goldline Pharmaceutical Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Goldline Pharmaceutical Limited
Goldline Pharmaceutical Limited is audited by SHAH & RAUT for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| SHAH & RAUT | blur-value | blur-value | blur-value |
Board of Directors of Goldline Pharmaceutical Limited
Goldline Pharmaceutical Limited is currently managed by 10 directors, with 5 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Swapan Khandelwal
Also directs:
Cherry Voyaging Private Limited, Activista Healthcare Private Limited, Nucleage Lifesciences Private Limited and 4 more
|
Whole-Time Director | 11 Apr 2011 | 15 Years 2 Months | Current |
|
Amol Laxmikant Mujumdar
Also directs:
Cherry Voyaging Private Limited
|
Managing Director | 02 Aug 2004 | 21 Years 11 Months | Current |
|
Mehul Hari Ranade
Also directs:
Mumukshu Management Services Llp, Jiya Eco-Products Limited, Asud Renewables Private Limited and 1 more
|
Director | 30 Sep 2024 | 1 Years 9 Months | Current |
| Prashant Shrikrishna Karkare | Director | 16 Jul 2013 | 12 Years 11 Months | Current |
|
Renuka Saurabh Borole
Also directs:
Jiya Eco-Products Limited, Dra Consultants Limited
|
Director | 30 Sep 2024 | 1 Years 9 Months | Current |
|
Shraddha Kiran Kulkarni
Also directs:
Urban Enviro Waste Management Limited
|
Director | 17 Oct 2024 | 1 Years 8 Months | Current |
Financials of Goldline Pharmaceutical Limited FY 2025 filings available
Goldline Pharmaceutical Limited reported revenue of ₹28.06 Cr (up 19% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Goldline Pharmaceutical Limited
As of FY 2023, Goldline Pharmaceutical Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Goldline Pharmaceutical Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Dec 2024 | Others | ₹42.1 Lakh | Open |
| 02 May 2022 | Bank of India | ₹46 Lakh | Open |
| 16 Jan 2013 | Bank of India | ₹7.65 Cr | Open |
| 27 Dec 2013 | Bank of India | ₹8 Lakh | Satisfied |
| 17 Feb 2011 | State Bank of India | ₹3.45 Cr | Satisfied |
Total charge records: 5 View all charges
Employees and EPFO Compliance at Goldline Pharmaceutical Limited
Goldline Pharmaceutical Limited has a workforce of 85 employees as of Apr 07, 2024.
Employee Count & EPFO Data of Goldline Pharmaceutical Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Goldline Pharmaceutical Limited
GSTIN & GST Filing Data of Goldline Pharmaceutical Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Goldline Pharmaceutical Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Goldline Pharmaceutical Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Goldline Pharmaceutical Limited
MSME Payment Delays by Goldline Pharmaceutical Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Goldline Pharmaceutical Limited
Subsidiaries & Group Companies of Goldline Pharmaceutical Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Goldline Pharmaceutical Limited with ownership details.
MCA Filings & Documents of Goldline Pharmaceutical Limited
MCA Filings & Documents of Goldline Pharmaceutical Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Goldline Pharmaceutical Limited
Frequently Asked Questions about Goldline Pharmaceutical Limited
Goldline Pharmaceutical Limited is an active public limited company in the pharma sector based in Nagpur, Maharashtra, India. It was incorporated on 02 August 2004 (22+ years old) and is registered under CIN U51397MH2004PLC147806. The company has 85 employees.
Goldline Pharmaceutical Limited reported revenue of ₹28.06 Cr for FY 2025 (up 19.00% YoY).
The current directors of Goldline Pharmaceutical Limited are:
- Swapan Khandelwal
- Amol Laxmikant Mujumdar
- Mehul Hari Ranade
- Ruchi Sanket Modi
- Prashant Shrikrishna Karkare
- Renuka Saurabh Borole
- Shraddha Kiran Kulkarni
- Prashant Vithalrao Rahate
- Avinash Pandurang Ambulkar
- Dipti Sharad Bhusari
The primary industry of Goldline Pharmaceutical Limited is pharma. The company specifically operates in pharmaceutical retailers and distributors. The company is currently active in this sector.
Goldline Pharmaceutical Limited can be reached at the registered office: 103 F – 1Leelaapartmentshilpahsgsociety Nearsaptagirinagar Shanidham Narend, Ra Nagar, Nagpur, Maharashtra, India – 440015, or through the website goldlinepharma.in.
The authorised capital is ₹13.5 Cr, and the paid-up capital is ₹8.71 Cr.